Journal of Cellular and Molecular Immunology

Commentary Open Access

Integrative strategies combining oncolytic adenovirus, anti-PD-1, and chemotherapy in a 3D TNBC model

Mariangela Garofalo , Lukasz Kuryk

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant subtypes of breast cancer and is characterized by a lack of expression of estrogen receptors, progesterone receptors, and HER2, making targeted therapies ineffective [1,2]. The limited treatment options for TNBC primarily rely on chemotherapy, and while the addition of immune checkpoint inhibitors (ICIs), such as anti-PD-1 antibodies, has shown promise in other cancers, the response in TNBC has been modest [3,4]. This publication by Kuryk et al. 

J Cell Mol Immunol, 2026, Volume 5, Issue 1, p7-9 | DOI: 10.46439/immunol.5.042

Review Article Open Access

Immunotherapy as a treatment to confront the ongoing opioid epidemic- A review

Nachum Dafny

Substance use disorders continue to be major medical and social problems worldwide. The use of opiate has grown substantially over the past three decades reaching the dimensions of a global epidemic. Current drug treatments have many limitations: long treatment times, dependency on treatment medications, relapses after treatment, high costs of treatment, and non-adherence by affected persons.

J Cell Mol Immunol, 2022, Volume 1, Issue 1, p20-27 | DOI: 10.46439/immunol.1.006